Genitourinary Cancer

MD IQ

Conference Coverage

PARP inhibitor prolongs PFS in mCRPC

BARCELONA – The PROfound trial shows that targeted therapy can be effective against metastatic castration-resistant prostate cancer bearing DNA...

Pages